Postmenopausal Osteoporosis
📧 Sign up to get email alerts when something new happens for Postmenopausal Osteoporosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2010-01-26Clinical Trial Update: Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis [Phase 3]
Phase 3 trial of denosumab (AMG 162) for prevention of postmenopausal osteoporosis completed; results were posted 2010-01-26.
-
FDA label_change · 2009-12-31FDA Approved: ACTONEL — Supplemental Application (Allergan, Inc.)
FDA approved Allergan's supplemental NDA for Actonel (risendronate sodium) to update the labeling, potentially adding or revising indication…
-
FDA approval · 2009-12-30FDA Approved: PREMPRO — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for PREMPRO (conjugated estrogens and medroxyprogesterone acetate) filed by Wyeth Pharmaceutical…
-
CLINICAL_TRIALS trial_result · 2009-12-15Clinical Trial Update: Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women [Phase 3]
Phase 3 trial of risedronate for prevention of osteoporosis in osteopenic postmenopausal women has completed.
-
CLINICAL_TRIALS trial_result · 2009-12-15Clinical Trial Update: Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women [Phase 3]
Phase 3 trial evaluating risedronate 75 mg given on two consecutive days each month for postmenopausal osteoporosis completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2009-12-07Clinical Trial Update: POWER Point of Care Effect on Satisfaction of Treatment [Phase 4]
Phase 4 trial completed, evaluating how POWER Point of Care affects treatment satisfaction in postmenopausal osteoporosis patients, sponsore…
-
CLINICAL_TRIALS trial_result · 2009-10-05Clinical Trial Update: A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation [Phase 1]
This is a Phase 1 study evaluating the effect of food on the intermittent formulation of ONO-5920/YM529 for osteoporosis. The trial status i…
-
FDA approval · 2009-07-23FDA Approved: ACTONEL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Actonel (risendronate sodium) from Allergan, Inc., approving changes to the product labeling und…
-
CLINICAL_TRIALS trial_result · 2009-07-21Clinical Trial Update: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva [Phase 4]
Phase 4 trial update reporting results for Bonviva (ibandronate) in women with postmenopausal osteoporosis who were previously treated with …
-
FDA approval · 2009-05-18FDA Approved: PREMPRO — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for PREMPRO (conjugated estrogens and medroxyprogesterone acetate) from Wyeth Pharmaceuticals (Pfize…
-
CLINICAL_TRIALS trial_result · 2009-04-29Clinical Trial Update: Risedronate in the Prevention of Osteoporosis in Postmenopausal Women [Phase 4]
This Phase 4 trial update reports on risedronate for the prevention of osteoporosis in postmenopausal women; the study status is completed.
-
CLINICAL_TRIALS trial_result · 2009-01-28Clinical Trial Update: Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D) [Phase 4]
Phase 4 trial evaluating the effect of monthly 150 mg oral ibandronate on bone structural properties in postmenopausal osteoporosis; study c…
-
CLINICAL_TRIALS trial_result · 2009-01-21Clinical Trial Update: Combination Osteogenic Therapy in Established Osteoporosis [Phase 2]
Phase 2 trial update on a combination osteogenic therapy for osteoporosis, including postmenopausal osteoporosis.
-
CLINICAL_TRIALS trial_result · 2008-12-11Clinical Trial Update: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of PTH134 in healthy postmenopausal…
-
FDA approval · 2008-11-17FDA Approved: CALCITONIN SALMON — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original ANDA for Calcitonin Salmon, authorizing a generic version of the drug for its approved uses.
-
FDA approval · 2008-10-30FDA Approved: EVAMIST — Supplemental Application (Padagis US LLC)
The FDA approved a supplemental application for EVAMIST, a transdermal estradiol product, under Padagis US LLC.
-
FDA approval · 2008-10-08FDA Approved: FOSAMAX — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for FOSAMAX (alendronate sodium) submitted by Organon LLC.
-
FDA approval · 2008-08-04FDA Approved: ALENDRONATE SODIUM — Original Application (EXELAN PHARMACEUTICALS INC.)
FDA approved the original application for alendronate sodium (Exelan Pharmaceuticals Inc.), making this generic osteoporosis therapy availab…
-
FDA approval · 2008-08-04FDA Approved: ALENDRONATE SODIUM — Original Application (Aurobindo Pharma Limited)
FDA approves the original application for alendronate sodium from Aurobindo Pharma Limited as a generic therapy.
-
FDA approval · 2008-06-25FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for teriparatide submitted by Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2008-05-01Clinical Trial Update: Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis [Phase 3]
This document reports the completion of a Phase 3 clinical trial evaluating teriparatide for osteoporosis in postmenopausal women.
-
CLINICAL_TRIALS trial_result · 2008-05-01Clinical Trial Update: Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis [Phase 3]
A Phase 3 trial comparing raloxifene hydrochloride to placebo for postmenopausal osteoporosis has completed.
-
FDA approval · 2008-04-22FDA Approved: ACTONEL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Actonel (risedronate sodium) submitted by Allergan, Inc., resulting in an approved update to the…
-
CLINICAL_TRIALS trial_result · 2008-03-11Clinical Trial Update: A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis [Phase 4]
Phase 4 study assessing satisfaction with Actonel in postmenopausal women with osteoporosis has completed.
-
CLINICAL_TRIALS trial_result · 2008-03-11Clinical Trial Update: Risedronate Sodium in Post Menopausal Osteoporosis [Phase 4]
A Phase 4 clinical trial evaluating risedronate sodium for postmenopausal osteoporosis has completed.